bioAffinity Technologies, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Market Information Our Common Stock, par value $0.007 per share (the “Common Stock”) trades under the symbol “BIAF.” Our tradeable warrants, each to purchase one share of Common Stock (collectively, the “Tradeable Warrants”), trade under the symbol “BIAFW.” Our Common Stock and Tradeable Warrants trade on The Nasdaq Capital Market. Holders of Record As of March 17, 2025, there were approximately 92 holders of record of shares of our Common Stock. This number does not reflect the beneficial holders of our Common Stock who hold shares in street name through brokerage accounts or other nominees. Dividends We have never declared or paid any cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate declaring or paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our Board of Directors and will depend on then-existing conditions, including our financial condition, results of operations, contractual restrictions, capital requirements, business prospects, and other factors our Board of Directors may deem relevant. Unregistered Sales of Equity Securities We did not sell any equity securities during the quarter ended December 31, 2024, in transactions that were not registered under the Securities Act other than as previously disclosed in our filings with the SEC. Securities Authorized for Issuance Under Equity Compensation Plans The following table presents information as of December 31, 2024, with respect to shares of our Common Stock that may be issued under our equity incentive plans. Plan category Number of securities to be issued upon exercise of outstanding options, warrants, and rights Weighted-average exercise price of outstanding options, warrants, and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (a) (b) (c) Equity compensation plans approved by security holders 2024 Equity Incentive Plan 519,792 $ 2.00 1,480,208 2014 Equity Incentive Plan 380,132 $ 5.78 — Equity compensation plans not approved by security holders — — — Total 899,924 $ 3.59 1,480,208 Item 6. [Reserved.]